American journal of preventive cardiology最新文献

{"title":"Associations between potassium, arterial stiffness, and risk of cardiovascular disease in the Jackson Heart Study","authors":"Ranee Chatterjee ,&nbsp;Clemontina A Davenport ,&nbsp;Ervin R. Fox ,&nbsp;Ramachandran S. Vasan ,&nbsp;Gary F Mitchell","doi":"10.1016/j.ajpc.2025.100955","DOIUrl":"10.1016/j.ajpc.2025.100955","url":null,"abstract":"<div><h3>Background</h3><div>Potassium (K) measures are associated with cardiovascular disease (CVD) risk factors, particularly blood pressure (BP). Arterial stiffness is a pre-clinical marker of CVD risk. We sought to study associations of K measures with arterial stiffness and CVD risk in a population at high-risk of CVD.</div></div><div><h3>Methods</h3><div>We studied participants from the Jackson Heart Study (JHS), a longitudinal cohort of adults racially minoritized as Black, who were without CVD at Visit 1 (2000–2004). We compared characteristics between participants with low-normal (lowK) (≤4.0 mmol/L) vs. high-normal (highK) (&gt;4.0 mmol/L) serum K. We used multivariable regression to examine associations of serum and dietary K at Visit 1 with arterial stiffness [brachial artery pulse pressure (PP) and carotid-femoral pulse wave velocity (CFPWV)], measured between 2012 and 2017, incident CVD overall over up to 15 years of follow-up, and individual CVD outcomes.</div></div><div><h3>Results</h3><div>We included 4035 JHS participants in our analyses; mean age was 54 years, 64 % were female. Participants with highK as compared to lowK had lower mean baseline BP and had reduced arterial stiffness. In adjusted models, higher serum K (per standard deviation increase) was associated with lower CFPWV [estimate (95 % CI) -1.66 (-2.88, -0.44)]. There was a significant difference in cumulative incidence of CVD, with the highK group having lower risk (<em>P</em> = 0.047); however, we did not observe statistically significant associations between serum K and any CVD outcomes after multivariable adjustment. We found no significant associations between dietary K and arterial stiffness or incident CVD.</div></div><div><h3>Conclusions</h3><div>In this cohort of Black adults, higher serum K was significantly associated with lower arterial stiffness. Further study is needed to assess the relationship between K's association with arterial stiffness and future CVD risk.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"22 ","pages":"Article 100955"},"PeriodicalIF":4.3,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143628351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Generalizability of VICTORION-1 PREVENT enrollment criteria to the United States population","authors":"Rahul Aggarwal ,&nbsp;Deepak L. Bhatt ,&nbsp;Marc P. Bonaca ,&nbsp;Catrin Deck ,&nbsp;Anastasia Lesogor ,&nbsp;Manesh R. Patel ,&nbsp;Erik S.G. Stroes ,&nbsp;Pam R. Taub ,&nbsp;Stephan Windecker","doi":"10.1016/j.ajpc.2025.100957","DOIUrl":"10.1016/j.ajpc.2025.100957","url":null,"abstract":"<div><h3>Background</h3><div>VICTORION-1 PREVENT (V-1P) is an ongoing trial evaluating inclisiran for lipid lowering in patients with high cardiovascular (CV) risk without established atherosclerotic CV disease (ASCVD). This study evaluates the generalizability of V-1P enrollment criteria to the US population and their clinical comorbidity and CV risk factor burden.</div></div><div><h3>Methods</h3><div>Data from National Health and Nutrition Examination Surveys (2015-March 2020) were used to determine nationally representative estimates. Inclusion criteria were low-density lipoprotein cholesterol (LDL-C) of 70–189 mg/dL and a 10-year ASCVD risk of ≥20% or 7.5%-19.9% with two CV risk enhancers. The pooled cohort equations (PCE) was used to stratify ASCVD risk in primary analysis. Estimates of the US population were compared with the V-1P eligible population.</div></div><div><h3>Results</h3><div>The V-1P eligible population included 23,837,940 adults. Compared with US adults ages 40-79 years, V-1P eligible adults had higher mean 10-year ASCVD risk by PCE (21.1% [95% CI: 20.1%-22.2%] vs 10.0% [95% CI: 9.4%-10.6%]). The V-1P eligible population also had higher rates of hypertension (85.4% [95% CI: 81.6%-89.1%] vs 59.4% [95% CI: 56.7%-62.2%], diabetes (35.6% [95% CI: 31.3%-40.0%] vs 18.7% [95% CI: 16.9%- 20.5%]) and metabolic syndrome (81.6% [95% CI: 78.4%-84.7%] vs 51.1% [48.3%- 53.9%]). Adults meeting V-1P eligibility had high levels of LDL-C (117.8 mg/dL [95% CI: 114.3 mg/dL-121.2 mg/dL]) and low statin use (36.7% [95% CI: 31.9%-41.5%]).</div></div><div><h3>Conclusions</h3><div>Many primary prevention patients have high CV risk, significant comorbidity burden, and are eligible for lipid-lowering therapy, yet rates of treatment are low. Public health interventions to improve CV risk factor management are necessary.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"22 ","pages":"Article 100957"},"PeriodicalIF":4.3,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of long-term insulin variability before the onset of diabetes with cardiovascular outcomes in later life: Findings from the coronary artery risk development in young adults (CARDIA) study","authors":"Kun Zhang ,&nbsp;Chunlan Huang ,&nbsp;Junping Li ,&nbsp;Peibiao Mai ,&nbsp;Shuwan Xu ,&nbsp;Feifei Huang ,&nbsp;Wanbing He ,&nbsp;Huanji Zhang ,&nbsp;Yang Liu ,&nbsp;Weijing Feng","doi":"10.1016/j.ajpc.2025.100952","DOIUrl":"10.1016/j.ajpc.2025.100952","url":null,"abstract":"<div><h3>Background</h3><div>The important effects of variability of some physiological/biological characteristics (such as LDL cholesterol, blood pressure) on cardiovascular outcomes have been elucidated, while the role of insulin variability is undefined.</div></div><div><h3>Objectives</h3><div>To investigate the associations of long-term fasting insulin variability during young adulthood before the onset of diabetes with subsequent cardiovascular outcomes in middle age.</div></div><div><h3>Methods</h3><div>We included 3,983 CARDIA (Coronary Artery Risk Development Study in Young Adults) participants aged 18 to 30 years with at least three fasting insulin measurements. Intra-individual fasting insulin variability was defined by the average real variability (ARV) of insulin and standard deviation (SD) of insulin during 30-year follow-up. The presence and the degree of coronary artery calcification (CAC) were assessed by computed tomography at year 25. Incident cardiovascular disease (CVD) and all-cause mortality were adjudicated.</div></div><div><h3>Results</h3><div>After multivariable adjustment, comparing high versus low tertile of insulin ARV, the hazard of CVD increased by 65 % (HR, 1.65; 95 % CI, 1.13–2.39) and all-cause mortality by 97 % (HR, 1.97; 95 % CI, 1.38–2.82). Higher tertile of insulin ARV was associated with significantly worse degree of CAC (β =0.1; 95 % CI, 0.03–0.18) but not with the presence of CAC (<em>P</em> = 0.197). Similar results were also observed in insulin SD.</div></div><div><h3>Conclusion</h3><div>High long-term insulin variability in young adulthood before the onset of diabetes was associated with an increased risk of CVD and all-cause mortality in later life, independent of average FG, HOMA-IR and other established cardiovascular risk factors. Long-term insulin variability was associated with the degree but not the presence of CAC.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"22 ","pages":"Article 100952"},"PeriodicalIF":4.3,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143631805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editors’ Message – March 2025","authors":"Nathan D. Wong ,&nbsp;Erin D. Michos","doi":"10.1016/j.ajpc.2025.100962","DOIUrl":"10.1016/j.ajpc.2025.100962","url":null,"abstract":"","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100962"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143680193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rethinking cardiovascular risk: The emerging role of lipoprotein(a) screening","authors":"Victoria Clair ,&nbsp;Francis M. Zirille ,&nbsp;Edward Gill","doi":"10.1016/j.ajpc.2025.100945","DOIUrl":"10.1016/j.ajpc.2025.100945","url":null,"abstract":"<div><div>Lipoprotein(a) [Lp(a)] is a genetically inherited, independent risk factor for cardiovascular disease (CVD), affecting approximately 20–25% of the global population. Elevated Lp(a) levels are associated with a 2–3-fold increased risk of myocardial infarction and aortic valve stenosis, comparable to the risk seen in individuals with familial hypercholesterolemia. Despite its clinical relevance, the integration of Lp(a) screening into routine practice has been limited by inconsistent measurement techniques and a lack of targeted treatments. Recent advancements, including improved assays and the development of potential Lp(a)-lowering therapies, have renewed focus on the importance of Lp(a) screening.</div><div>This review aims to clarify the role of Lp(a) in cardiovascular health by examining current evidence on who should be screened, when screening should occur, and the most accurate methods for measuring Lp(a). Key recommendations include universal, one-time screening for adults, selective screening for high-risk pediatric patients, and special considerations for individuals with conditions such as familial hypercholesterolemia and chronic kidney disease. Advances in assay technology now allow for more precise Lp(a) measurement, supporting better risk stratification. Additionally, emerging therapies that specifically target elevated Lp(a) levels could lead to more personalized management of CVD risk.</div><div>Our findings support the integration of Lp(a) screening into routine cardiovascular risk assessment, highlighting its potential to improve early detection and prevention strategies across diverse patient populations.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100945"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143527328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment strategies and LDL cholesterol target attainment in patients with statin intolerance: Insights from the multicentre statin intolerance registry","authors":"Paulina E. Stürzebecher ,&nbsp;Julius L. Katzmann ,&nbsp;Ionna Gouni-Berthold ,&nbsp;Christina Mateev ,&nbsp;Ole Frenzel ,&nbsp;Ulrike Schatz ,&nbsp;Andrea Baessler ,&nbsp;Wolfgang Koenig ,&nbsp;Stephan H. Schirmer ,&nbsp;Irina Müller-Kozarez ,&nbsp;Oliver Weingärtner ,&nbsp;Ursula Kassner ,&nbsp;Ulrich Laufs ,&nbsp;Statin Intolerance Registry investigators","doi":"10.1016/j.ajpc.2025.100953","DOIUrl":"10.1016/j.ajpc.2025.100953","url":null,"abstract":"<div><h3>Objective and methods</h3><div>Statin intolerance (SI) is an important cause of insufficient low-density lipoprotein cholesterol (LDL-C) target attainment. Contemporary treatment strategies and symptoms in patients with SI are incompletely understood. We report baseline lipid-lowering therapies (LLTs) and LDL-C target attainment in the Statin Intolerance Registry, an observational, prospective, multicenter study that recruited 1,111 patients with SI between 2021 and 2023 in Germany.</div></div><div><h3>Results</h3><div>The mean age was 66.1 (SD 9.9) years, 57.7 % were female. At study inclusion, 83.1 % received at least one LLT, and 47.0 % received combination LLT. A higher number of LLTs was associated with lower LDL-C, lower systolic blood pressure, more atherosclerotic disease, more elevations of creatine kinase and liver enzymes but not with impaired quality of life as measured by EuroQol (EQ-5D-5L). PCSK9 inhibitors were most frequently prescribed (48.0 %), followed by ezetimibe (39.2 %), statins (26.9 %), most commonly rosuvastatin, and bempedoic acid (25.4 %). Patients who had been prescribed multiple statins before were more likely to take a statin at baseline. Patients on a statin, even at low intensity, had lower LDL-C levels compared to patients without statin therapy (mean [SD] 2.4 [1.2] vs. 2.9 [1.6] mmol/L, <em>p</em> &lt; 0.001). Significantly more men than women achieved the LDL-C target (21.7 % vs. 11.4 %, <em>p</em> &lt; 0.001, total cohort: 15.8 %).</div></div><div><h3>Conclusion</h3><div>LDL-C target attainment is low in patients with SI, especially among women, despite high cardiovascular risk. The use of a greater number of LLTs, including statins, is not associated with reduced quality of life but is associated with lower LDL-C levels.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100953"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143579848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individualized prediction of atrial fibrillation onset risk based on lifelogs","authors":"Takehiro Kimura ,&nbsp;Masahiro Jinzaki ,&nbsp;Hiroshi Miyama ,&nbsp;Kenji Hashimoto ,&nbsp;Terumasa Yamashita ,&nbsp;Yoshinori Katsumata ,&nbsp;Seiji Takatsuki ,&nbsp;Keiichi Fukuda ,&nbsp;Masaki Ieda","doi":"10.1016/j.ajpc.2025.100951","DOIUrl":"10.1016/j.ajpc.2025.100951","url":null,"abstract":"<div><h3>Background and Objective</h3><div>The Apple Watch alerts users to irregular heart rhythms and potential atrial fibrillation (AF), but delays in obtaining electrocardiograms (ECGs) after notifications can impede accurate disease diagnosis. We aimed to predict personalized AF risk using continuous Apple Watch lifelog data to facilitate timely ECG acquisition. We conducted two analyses: Keio and national. In the Keio analysis, AF patients underwent continuous 2-week Holter ECG monitoring, and a machine-learning model combining gradient-boosting decision trees and deep learning was developed. The national analysis recruited Apple Watch users across Japan to assess the model; data and survey responses were collected for seven days via a dedicated iPhone app.</div></div><div><h3>Results</h3><div>A total of 100 subjects (age: 63.9 ± 12.4 years, AF burden: 37.7 %) participated in the Keio analysis, while 8,935 subjects participated in the national analysis. Significant differences in Apple Watch data, including pulse rate (<em>p</em> &lt; 0.001) and step count (<em>p</em> &lt; 0.001), were observed between days with and without AF onset. Healthcare data measured by the Apple Watch, including sleep patterns, were significantly correlated with subjective survey responses (<em>p</em> &lt; 0.001) and incorporated into the model. The model achieved an F-value of 90.7 % compared to diagnosis based on a 2-week Holter ECG. The model showed an additive benefit to Apple Watch irregular-rhythm notifications for AF detection (irregular-rhythm notification vs. model: 68.8 % vs. 88.2 % for paroxysmal AF and 84.4 % vs. 100.0 % for persistent AF).</div></div><div><h3>Conclusions</h3><div>Apple Watch-derived lifelogs enabled individualized AF onset risk assessment and the development of a machine-learning model for optimizing ECG timing for early AF detection.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100951"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143519874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The burden of cardiovascular disease in children in Asian countries (1990–2021): Systematic analysis and projection of the burden of disease","authors":"Chenyang Li,&nbsp;Shiyi Lei,&nbsp;Lingjuan Liu,&nbsp;Yuxing Yuan,&nbsp;Jie Tian","doi":"10.1016/j.ajpc.2025.100956","DOIUrl":"10.1016/j.ajpc.2025.100956","url":null,"abstract":"<div><h3>Background</h3><div>Cardiovascular disease (CVD) is the leading global cause of death and health loss. The epidemiology and factors influencing CVD in children are unique, making it essential to first evaluate current and future trends to guide interventions and reduce the disease burden.</div></div><div><h3>Objective</h3><div>To analyze the incidence, mortality, and disability-adjusted life years (DALY) of CVD in children aged 0–14 from 1990 to 2021, and explore global disease burden, risk factors, and trends over the next 30 years. The study focuses on China, Japan, South Korea, India, and Singapore to aid in developing targeted prevention and treatment strategies.</div></div><div><h3>Methods</h3><div>Using data from the Global Burden of Disease Study (GBD) 1990–2021, we assessed age- and sex-specific morbidity, mortality, and DALY of CVD in Asian children aged 0–14 and computed the EAPC. We analyzed risk factors, specific causes, and projected prevalence trends through 2050 using the Bayesian Age-Period-Cohort (BAPC) model.</div></div><div><h3>Results</h3><div>From 1990 to 2021, CVD incidence among Asian children aged 0–14 decreased by 8.03 % (95 % UI:13.63 to -4.02). Mortality saw a significant drop of 67.98 % (95 % UI:73.73 to -62.23), with the greatest decline in children aged 2–4, and the highest death rate in those under 1 year. Disability and mortality patterns were similar across gender, age, etiology, and overall trends. In 2021, South Asia had the highest rates of morbidity, mortality, and disability. Rates varied significantly, with Mongolia exhibiting the highest rate and Cyprus the lowest, showing a sixfold difference. Rheumatic heart disease (RHD) and intracerebral hemorrhage were the most critical diseases needed attention. Abnormal temperatures were identified as a risk factor associated with CVD outcomes in children. The burden of CVD is projected to increase in various regions and countries across Asia.</div></div><div><h3>Conclusion</h3><div>The burden of CVD continues to challenge children aged 0–14 in Asia. Enhancing our understanding of pediatric CVD epidemiology, addressing risk factors, and reinforcing prevention and control measures are essential for reducing this burden.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100956"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143600895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Population cessation of aspirin use for the prevention of cardiovascular disease","authors":"Stephanea Roeser ,&nbsp;Sue Duval ,&nbsp;Russell V. Luepker ,&nbsp;Milton Eder ,&nbsp;John R. Finnegan ,&nbsp;Jeremy R. Van't Hof","doi":"10.1016/j.ajpc.2025.100941","DOIUrl":"10.1016/j.ajpc.2025.100941","url":null,"abstract":"<div><h3>Importance</h3><div>Aspirin use for primary prevention of cardiovascular diseases (CVD) is widespread with over a third of the adult population using despite guidelines recommending against.</div></div><div><h3>Objective</h3><div>This population-based research documents rates of use and reasons for cessation from 2015 to 2020, a period when guidelines changed.</div></div><div><h3>Design</h3><div>Three cross-sectional telephone surveys were conducted during 2015, 2017, and 2019–20.</div></div><div><h3>Setting</h3><div>A population-based survey in the states of Iowa, Minnesota, North Dakota, South Dakota, and Wisconsin.</div></div><div><h3>Participants</h3><div>The surveys included non-institutionalized resident adults ages 55–79 for women and 45–79 for men with landline telephones.</div></div><div><h3>Main Outcomes and Measures</h3><div>The analysis included 8,197 participants, 4,161 women and 4,036 men after excluding those with a history of cardiovascular disease (secondary prevention). Aspirin use for primary prevention was stable for the first two survey years (39 % in 2015 and 41 % in 2017) but fell significantly to 34 % in the final survey (2019–2020). The most common reason for cessation was “doctor's advice” (38 % of quitters) followed by “heard negative news” with a significant increase from 2015 to 2020 (4 % to 29 % of quitters).</div></div><div><h3>Conclusions and Relevance</h3><div>Despite recent research findings and new guidelines, aspirin is still widely used for primary prevention of CVD in the general population. A combination of slow diffusion and implementation of guidelines, self-medication, and wide availability of low-cost aspirin underlies these trends. Physician advice is effective but more is needed. The influence of the popular media is also substantial. Appropriate implementation of aspirin guidelines requires additional clinician effort.</div></div><div><h3>Trial Registration</h3><div>Clinicaltrials.gov registered on December 1, 2014, NCT02607917</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100941"},"PeriodicalIF":4.3,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143519873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and clinical characteristics of patients with hsCRP testing and test-confirmed systemic inflammation among individuals with atherosclerotic cardiovascular disease with or without chronic kidney disease in the United States (PLUTUS)","authors":"Lei Lv ,&nbsp;Jigar Rajpura ,&nbsp;Meixia Liu ,&nbsp;Matt Strum ,&nbsp;Benjamin Chastek ,&nbsp;Jonathan Johnson ,&nbsp;Ty J. Gluckman","doi":"10.1016/j.ajpc.2025.100950","DOIUrl":"10.1016/j.ajpc.2025.100950","url":null,"abstract":"<div><h3>Background</h3><div>Systemic inflammation (SI) is a risk factor for atherosclerotic cardiovascular disease (ASCVD) and is most commonly assessed by measuring levels of high-sensitivity C-reactive protein (hsCRP).</div></div><div><h3>Objective</h3><div>This study aimed to determine hsCRP testing rates and SI prevalence in patients with ASCVD and in a subset of patients with chronic kidney disease (CKD).</div></div><div><h3>Methods</h3><div>This was a retrospective, cross-sectional analysis using US-based data from the Optum® de-identified Electronic Health Record data set (Optum® EHR; 1/1/2017–12/31/2021). hsCRP testing rates and SI prevalence (hsCRP ≥2 to &lt;10 mg/L) were evaluated by calendar year. Demographics, comorbidities, and treatment patterns were compared between patients with ASCVD, ASCVD + CKD, and ASCVD + stage 3/4 CKD, with and without SI.</div></div><div><h3>Results</h3><div>1,658,476 patients with ASCVD were eligible for study inclusion. Per calendar year, 44.9 %-68.8 % and 14.9 %-18.9 % of patients had any CKD and stage 3/4 CKD, respectively. hsCRP testing was performed in 0.87 %-0.98 % (ASCVD), 0.90 %-1.17 % (ASCVD + CKD), and 0.99 %-1.41 % (ASCVD + stage 3/4 CKD) of patients. SI was present in 37.16 %-38.62 % (ASCVD), 40.61 %-44.44 % (ASCVD + CKD), and 49.44 %-53.92 % (ASCVD + stage 3/4 CKD) of tested patients. Among those with SI, patients with CKD had a greater comorbidity burden than those without.</div></div><div><h3>Conclusion</h3><div>While rates of hsCRP testing were low in patients with ASCVD, the prevalence of SI was high in hsCRP-tested patients with ASCVD, irrespective of CKD presence or severity. Given the low rate of testing, patients with SI may not be identified and treated.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"21 ","pages":"Article 100950"},"PeriodicalIF":4.3,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143471240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}